Literature DB >> 24063832

Effect of body mass index on 30- and 365-day complication and survival rates of transcatheter aortic valve implantation (from the FRench Aortic National CoreValve and Edwards 2 [FRANCE 2] registry).

Masanori Yamamoto1, Gauthier Mouillet, Atsushi Oguri, Martine Gilard, Marc Laskar, Helene Eltchaninoff, Jean Fajadet, Bernard Iung, Patrick Donzeau-Gouge, Pascal Leprince, Alain Leuguerrier, Alain Prat, Michel Lievre, Karine Chevreul, Jean-Luc Dubois-Rande, Emmanuel Teiger.   

Abstract

The "obesity paradox" that patients with high body mass index (BMI) have good prognoses remains controversial. This study aimed to assess the impact of BMI on clinical outcomes in patients who underwent transcatheter aortic valve implantation (TAVI). Data from the French national TAVI registry were collected for 3,072 patients who underwent TAVI from January 2010 to October 2011. The patients were categorized into 4 groups according to BMI (kg/m(2)): underweight (<18.5 kg/m(2)), normal weight (18.5 to 25 kg/m(2)), overweight (25 to 30 kg/m(2)), and obese (>30 kg/m(2)). Thereafter, clinical outcomes were compared among the 4 groups. The BMI distribution was 3.1% (n = 95), 44.1% (n = 1,355), 34.2% (n = 1,050), and 18.6% (n = 572). Although the 4 groups greatly differed in baseline clinical background, they had similar procedural success rates (95.8%, 97.1%, 97.3%, and 95.6%, p = 0.23). Major vascular complication was significantly associated with the underweight patients after adjusting for the other potential confounders (odds ratio 2.33, 95% confidence interval 1.17 to 4.46, p = 0.016). The cumulative postoperative survival rates were increasing across the 4 groups at 30 days (83.2%, 88.9%, 91.6%, and 93.0%, p = 0.003) and 1 year (67.9%, 73.6%, 77.4%, and 80.3%, p = 0.006). In a multivariate Cox regression analysis, the overweight and obese patients were independently associated with superior cumulative survival rate at 1 year (hazard ratios 0.74 and 0.71, 95% confidence intervals 0.57 to 0.97 and 0.59 to 0.87, p = 0.050 and 0.029, respectively). In conclusion, major morbidity and 1-year mortality were less in overweight and obese patients than those classified as normal weight even in a TAVI cohort.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24063832     DOI: 10.1016/j.amjcard.2013.08.022

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Prognostic value of body mass index and body surface area on clinical outcomes after transcatheter aortic valve implantation.

Authors:  Mani Arsalan; Giovanni Filardo; Won-Keun Kim; John J Squiers; Benjamin Pollock; Christoph Liebetrau; Johannes Blumenstein; Jörg Kempfert; Arnaud Van Linden; Annika Arsalan-Werner; Christian Hamm; Michael J Mack; Helge Moellmann; Thomas Walther
Journal:  Clin Res Cardiol       Date:  2016-08-17       Impact factor: 5.460

2.  The MAGGIC risk score predicts mortality in patients undergoing transcatheter aortic valve replacement: sub-analysis of the OCEAN-TAVI registry.

Authors:  Hirofumi Hioki; Yusuke Watanabe; Ken Kozuma; Hideyuki Kawashima; Fukuko Nagura; Makoto Nakashima; Akihisa Kataoka; Masanori Yamamoto; Toru Naganuma; Motoharu Araki; Norio Tada; Shinichi Shirai; Futoshi Yamanaka; Akihiro Higashimori; Kazuki Mizutani; Minoru Tabata; Kensuke Takagi; Hiroshi Ueno; Kentaro Hayashida
Journal:  Heart Vessels       Date:  2019-05-29       Impact factor: 2.037

3.  The obesity paradox: association of obesity with improved survival in medically managed severe aortic stenosis.

Authors:  Jinghao Nicholas Ngiam; Nicholas Ws Chew; Benjamin Yong-Qiang Tan; Hui Wen Sim; Ching-Hui Sia; William Kf Kong; Tiong-Cheng Yeo; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2020-12-02       Impact factor: 3.331

4.  Does the "obesity paradox" exist after transcatheter aortic valve implantation?

Authors:  Zeng-Rong Luo; Han-Fan Qiu; Liang-Wan Chen
Journal:  J Cardiothorac Surg       Date:  2022-06-13       Impact factor: 1.522

5.  Transcatheter Heart Valve Selection and Permanent Pacemaker Implantation in Patients With Pre-Existent Right Bundle Branch Block.

Authors:  Lennart van Gils; Didier Tchetche; Thibault Lhermusier; Masieh Abawi; Nicolas Dumonteil; Ramón Rodriguez Olivares; Javier Molina-Martin de Nicolas; Pieter R Stella; Didier Carrié; Peter P De Jaegere; Nicolas M Van Mieghem
Journal:  J Am Heart Assoc       Date:  2017-03-03       Impact factor: 5.501

6.  Effect of body mass index on clinical outcome and all-cause mortality in patients undergoing transcatheter aortic valve implantation.

Authors:  M Abawi; R Rozemeijer; P Agostoni; R C van Jaarsveld; C S van Dongen; M Voskuil; A O Kraaijeveld; P A F M Doevendans; P R Stella
Journal:  Neth Heart J       Date:  2017-09       Impact factor: 2.380

7.  Predictors of early mortality after transcatheter aortic valve implantation.

Authors:  Didrik Kjønås; Gry Dahle; Henrik Schirmer; Siri Malm; Jo Eidet; Lars Aaberge; Terje Steigen; Svend Aakhus; Rolf Busund; Assami Rösner
Journal:  Open Heart       Date:  2019-04-23

8.  Association of body mass index and visceral fat with aortic valve calcification and mortality after transcatheter aortic valve replacement: the obesity paradox in severe aortic stenosis.

Authors:  Jennifer Mancio; Paulo Fonseca; Bruno Figueiredo; Wilson Ferreira; Monica Carvalho; Nuno Ferreira; Pedro Braga; Alberto Rodrigues; Antonio Barros; Ines Falcao-Pires; Adelino Leite-Moreira; Vasco Gama Ribeiro; Nuno Bettencourt
Journal:  Diabetol Metab Syndr       Date:  2017-10-19       Impact factor: 3.320

Review 9.  Preoperative frailty parameters as predictors for outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis.

Authors:  M S van Mourik; J F Velu; V R Lanting; J Limpens; B J Bouma; J J Piek; J Baan; J P S Henriques; M M Vis
Journal:  Neth Heart J       Date:  2020-05       Impact factor: 2.380

Review 10.  Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity.

Authors:  Kush P Patel; Thomas A Treibel; Paul R Scully; Michael Fertleman; Samuel Searle; Daniel Davis; James C Moon; Michael J Mullen
Journal:  Interv Cardiol       Date:  2022-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.